Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07496450 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
A Phase 3 study, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 4,000
- Enrollment target
NCT07496450: Recruiting Phase 3 study, sponsored by ModernaTX.
NCT07496450 is a Phase 3 study that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 4,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (418% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07496450, a Phase 3 study, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,000 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Primary Outcome
HAI Titer \>=1:40.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1018-H5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2027-01-28 |
| Phase | Phase 3 |
What NCT07496450 shows while recruiting
NCT07496450 is an interventional study that assigns participants to a tested intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (418% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07496450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07496450 about?
NCT07496450 is a clinical study titled "A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults". The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
What is the current status of trial NCT07496450?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,000 participants. The study started on 2026-03-23. Estimated completion is 2027-01-28.
What interventions are being tested in trial NCT07496450?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1018-H5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07496450?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07496450's enrollment target sits among peer trials
4,000 61st of 2000 higher than 1,938 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI